Behavioral and neuroendocrine reactivity of smokers to smoking vs non-smoking avatars in virtual reality (SMoking AvataR Trial) - SMART

Zentralinstitut für Seelische Gesundheit (ZI)0 个研究点目标入组 50 人开始时间: 2021年9月1日最近更新: 2024年8月19日

试验速览

暂无简介。

•Psychiatric comorbidity with psychiatric or psychotherapeutic treatment in the past 10 years (>1 psychiatric or psychotherapeutic treatment). Severe physical disease: cancer treatment during the past 10 years; metabolic disease (Addison's disease, Cushing's disease, hypogonadism, testosterone treatment); neurological disease (multiple sclerosis, Parkinson's disease, amyotrophic lateropathy, stroke during the past 5 years, traumatic brain disease with persistent neurological deficit); acute cardiovascular disease (first manifestation during the past 4 weeks), myocardial infarction, decompensated cardiac insufficiency; renal insufficiency; infectious disease currently being treated; rheumatological disease. Current use of medications for mental illness or use of drugs that interact with the central nervous system within a maximum of 5 half-lives. Known intolerance to high frequency flickering visual stimuli, as seen in very rare cases in certain forms of epilepsy (ascertainable through reported similar problems in past movie theater visits). Abstinence from cigarettes < 12 hours before planned study inclusion.

发起方